T1	Participants 606 662	Pregnant women with WHO stage 1, 2, or 3 HIV-1 infection
T2	Participants 561 596	in pregnant women infected with HIV
T3	Participants 838 866	Women were randomly assigned
T4	Participants 1442 1499	All infants received a 0Â·6 mL dose of nevirapine at birth
